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Expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific 
mitogen and a potent angiogenic factor, is upregulated by a variety of factors including 
hypoxia, growth factors and hormones. In the adrenal cortex, regulation of VEGF 
expression by the pituitary hormone ACTH ensures the maintenance of the organ 
vasculature. We have previously shown that ACTH evokes a rapid and transient 
increase in VEGF mRNA levels in primary adrenocortical cells through transcription-
independent mechanisms. We further demonstrated that the zinc finger RNA-binding 
protein Tis11b destabilizes VEGF mRNA through its 3’-untranslated region (3’-UTR) and 
that Tis11b is involved in the decay phase of ACTH-induced VEGF mRNA expression. 
In the present study, we attempted to determine the mechanisms underlying ACTH-
elicited increase in VEGF mRNA levels in adrenocortical cells. We show that ACTH 
triggers an increase in the levels of the mRNA-stabilizing protein HuR in the cytoplasm 
and a concomitant decrease in the levels of HuR in the nucleus. This process is 
accompanied by an increased association of HuR with the nucleocytoplasmic shuttling 
protein pp32, indicating that ACTH induces HuR translocation from the nuclear to the 
cytoplasmic compartment. Leptomycin B, a specific inhibitor of CRM1-dependent 
nuclear export of pp32, significantly reduced ACTH-induced VEGF mRNA levels. 
Furthermore, RNAi-mediated depletion of HuR in adrenocortical cells abrogated ACTH-
induced VEGF mRNA expression. Finally, we show that Tis11b and HuR exert 
antagonistic effects on VEGF 3’-UTR in vitro. Although both proteins could bind 
simultaneously on VEGF 3’-UTR, Tis11b markedly decreases HuR-binding to this RNA 
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instrumental to ACTH-induced expression of VEGF mRNA and that the nuclear export of 
HuR is a rate-limiting step in this process. HuR appears to transiently stabilize VEGF 
transcripts following ACTH stimulation of adrenocortical cells, and Tis11b appears to 








Vascular endothelial growth factor (VEGF) is the major angiogenic cytokine contributing 
to the regulation of physiological and pathological angiogenesis (1, 2). Its expression 
levels in mammalian cells are very tightly regulated. In fact, a 50% reduction of VEGF 
expression during embryogenesis, as observed in VEGF +/- heterozygous mice, results 
in lethality (3, 4). Reciprocally, overexpression of VEGF in adult tissues leads to the 
formation of angiomas and perturbs organ development (5). VEGF expression is 
regulated by a number of environmental factors including hypoxia, growth factors and 
several hormones (1, 6). With most of these factors, different levels of regulation are 
observed. First, VEGF transcription is activated by the binding of a number of 
transcription factors onto specific response elements located in the promoter of the 
VEGF gene. These include HIF-1α and AP-1 for the hypoxic response (7, 8), Sp1 and 
AP-2 for the growth factor response  (9, 10). Second, VEGF mRNA stability is regulated 
in response to some of these effectors through the binding of stabilizing and 
destabilizing proteins to AU-rich elements (AREs) located in the 3'-untranslated region 
(3'-UTR) of VEGF mRNA (11-14). Third, translation of VEGF mRNA into protein is also a 
controlled mechanism implying several alternative initiation codons (15). The choice of 
the preferential initiation codon is modified under hypoxic conditions (16) or under 
oncogenic transformation (17). These different levels of regulation may cooperate to 
amplify the effects of such or such regulator. For example, hypoxia-induced stimulation 
of VEGF expression results from both HIF-1α-mediated stimulation of transcription (7) 
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HuR is a ubiquitously expressed member of the ELAV (embryonic-lethal abnormal visual 
in Drosophila melanogaster) family of RNA binding proteins, which also comprises the 
neuron-specific proteins HuD, HuC and Hel-N1 (18, 19). The protein products of all four 
genes bind with high affinity and specificity to AREs in a variety of mRNAs, such as 
those encoding VEGF, c-fos, c-jun, IL-3, TNFα, and GM-CSF, and are believed to 
increase mRNA stability, mRNA translation or both (20, 21). While the precise 
mechanisms regulating HuR function in mRNA stabilisation are poorly understood, 
increasing evidence indicates that HuR function is intimately linked to its subcellular 
localization (22-24). Indeed, HuR contains three classical RNA-binding domains [RNA 
Recognition Motifs (RRM)]: the first two (RRM1 and RRM2) have been implicated in 
ARE recognition whereas the third (RRM3) has been suggested to bind the poly A tail of 
targets mRNA (25). The region located between RRM2 and RRM3, known as the hinge 
region, is essential for HuR subcellular localization. This region contains a shuttling 
domain, HNS (for HuR Nucleocytoplasmic Sequence) which is involved in the interaction 
of HuR with the acidic phosphoproteins ligands, pp32, SETα/β and APRIL (26). Like 
HuR, these proteins are primarily nucleoplasmic but shuttle between the nucleus and 
the cytoplasm. pp32 and APRIL contain domains homologous to nuclear export signals 
(NES) known to interact with CRM1 (Chromosomal region maintenance 1), the nuclear 
export receptor for the HIV-1 Rev protein. It has been shown recently that pp32 and 
APRIL mediate CRM1-dependent export of HuR in response to heat shock (27). 
We have previously reported that adrenocorticotropin (ACTH) rapidly and transiently 
stimulates VEGF expression by primary cultures of bovine adrenocortical cells (28). 
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independent as it was still observed in the presence of DRB, a potent transcription 
inhibitor (28). We then characterized Tis11b (TPA-inducible-sequence 11b) as a zinc 
finger RNA-destabilizing protein whose synthesis is also induced by ACTH, although 
slightly later than that of VEGF (29). We hypothesized that Tis11b might play a role in 
the control of VEGF mRNA stability. Indeed, we recently characterized the interaction 
between Tis11b and VEGF mRNA 3’-UTR, and identified a 75 bp sequence in this 3'-
UTR, containing two AU-rich elements, as the Tis11b binding-element (TBE) (30). We 
could show that Tis11b binding to TBE induces destabilization of VEGF mRNA, resulting 
in a reduction of VEGF mRNA half-life from 130 min down to 60 min. In the present 
work, we attempted to identify the mechanism by which ACTH induces VEGF mRNA. 
We identified HuR as a potential regulator and could establish that ACTH induces a 
rapid increase of HuR levels in the cytoplasm and a concomitant decrease of HuR levels 
in the nucleus. Moreover, co-immunoprecipitations experiments revealed that ACTH 
induces a molecular complex between the nucleocytoplasmic shuttling protein pp32 and 
HuR in the cytoplasm, suggesting that pp32 is involved in HuR accumulation in this 
compartment. Finally, as the Tis11b- and HuR-binding sites are quite close to each 
other on the VEGF mRNA 3’-UTR, we wondered whether these two proteins might 













Regulation of VEGF, Tis11b and HuR mRNAs expression by ACTH 
We have previously shown that ACTH rapidly and transiently induces the expression of 
VEGF in primary cultures of adrenocortical cells (28). Moreover, we recently observed 
that Tis11b, through its mRNA destabilizing-activity, is involved in the decay phase of 
ACTH-elicited VEGF mRNA levels (30). However, the mechanisms involved in the 
induction phase of VEGF mRNA remained to be determined. As this induction was still 
observed in the presence of the transcription inhibitor DRB (28), we postulated that 
stabilization of VEGF mRNA might be involved in this process. Since the ELAV family 
members HuC, HuD and Hel-N1 were reported as neural-specific RNA-stabilizing 
proteins, we focused on HuR, the ubiquitously expressed member of ELAV proteins. We 
first examined the possible involvement of HuR in ACTH-induced increase of VEGF 
mRNA. Fig. 1A illustrates an RT-PCR analysis of VEGF, Tis11b and HuR mRNA levels 
in adrenocortical cells stimulated with 10 nM ACTH for various periods of time ranging 
from 0 to 5 h. As previously reported (29), VEGF mRNA levels peaked after 2-3 h 
whereas the hormone induced the expression of Tis11b between 3 and 5 h of treatment 
(Fig. 1A and 1B). In contrast, HuR mRNA levels were unchanged over the period of 
ACTH stimulation (Fig. 1A and 1B). Northern blot analysis of HuR mRNA levels in 
ACTH-treated cells confirmed that they were very stable for up to 24 h of hormone 
treatment (maximal value reaching  137 ± 40 % of mRNA levels measured in non-
treated cells, n=3, data not shown).   
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The above results prompted us to examine whether ACTH could exert a post-
transcriptional effect by acting on HuR mRNA translation. As shown in Fig. 2A and 2B, 
following exposure of BAC cells to 10 nM ACTH, no significant changes were observed 
in HuR protein content of whole cell extracts. In contrast, ACTH induced a progressive 
increase in Tis11b protein content (Fig. 2A and 2B). This increase was apparent as early 
as 1 h after stimulation and peaked after 5-6 h. Tis11b protein expression remained 
slightly elevated 24 h after ACTH treatment (data not shown). 
 
ACTH increases cytoplasmic levels of HuR 
HuR appears predominantly located in the nucleus within all cell types examined so far 
(24). Moreover, HuR-induced stabilization of its mRNA targets is associated with an 
increase in cytoplasmic levels of HuR (24). To assess the subcellular distribution of HuR 
in BAC cells as well as the potential effect of ACTH on HuR localization, BAC cells were 
incubated with 10 nM ACTH for various periods of time ranging from 0 to 6 h, then 
subfractionated into nuclear and cytoplasmic fractions. As shown in Fig. 2C, HuR was 
weakly present in the cytoplasm (20 µg of cytoplasmic extracts) but was abundant in the 
nucleus (5 µg of nuclear extracts) of unstimulated cells. Quantitation of cytoplasmic and 
nuclear HuR revealed that ACTH treatment led to a 2 to 3-fold increase of cytoplasmic 
HuR as early as 30 min after stimulation and a concomitant decrease in nuclear HuR 
(Fig. 2D). Cytoplasmic HuR levels remained elevated for up to 3 h then decreased by 4 
h of stimulation. In unstimulated cells, HuR was estimated to be about 5 to 6-fold more 
abundant in the nucleus. Hybridization of the same membranes with antibodies 
recognizing cytoplasm- and nucleus-specific proteins (α-tubulin and lamin A/C, 
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fractions during cell fractionation (Fig. 2C). To determine the subcellular localization of 
Tis11b in BAC cells, the same blots were probed with affinity-purified polyclonal anti-
Tis11b antibodies (30). As shown on Fig. 2C, Tis11b was exclusively detected in the 
cytoplasmic fractions. Upon prolonged exposure of the membrane (15 min), a very weak 
Tis11b signal could be detected in the nuclear fractions (data not shown). Exposure of 
BAC cells to ACTH induced a robust increase in Tis11b protein levels in the cytoplasm 
(Fig. 2C), which was correlated to the induction of Tis11b that we observed in whole cell 
extracts (Fig. 2A).  
Altogether, these results indicate that ACTH treatment of BAC cells leads to a rapid 
increase of HuR protein content in the cytoplasm with a concomitant decrease of HuR 
protein content in the nucleus and to a delayed increase of Tis11b protein in the 
cytoplasm.  
 
HuR interacts with the nucleocytoplasmic shuttling protein pp32 in BAC cells  
In light of the observation that increases in cytoplasmic HuR are largely due to the 
CRM1-dependent export of nuclear HuR  which involves complexes between HuR and 
the nucleocytoplasmic shuttling proteins pp32 and/or APRIL (26, 27), we further tested 
whether these proteins might contribute to ACTH-induced accumulation of HuR in the 
cytoplasm using co-immunoprecipitation experiments. As we could not detect APRIL in 
whole BAC cell extracts (data not shown), we focused on pp32. Cytoplasmic and 
nuclear BAC extracts were exposed to anti-pp32 antibody. Probing the 
immunoprecipitates with anti-HuR antibody revealed that pp32 is associated with HuR in 
the cytoplasm and that ACTH treatment increases this association (Fig 3A and 3B). The 
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the nucleus, HuR-pp32 complexes are less abundant as compared to the cytoplasm and 
are not significantly altered by hormone treatment (Fig 3A and 3B). These results 
suggest that ACTH-induced increase in cytoplasmic HuR levels involves pp32-mediated 
HuR delocalization from the nucleus to the cytoplasm of BAC cells.  
 
Leptomycin B prevents ACTH-induced expression of VEGF mRNA  
CRM1-dependent nucleocytoplasmic shuttling of NES-containing proteins such as pp32 
has been shown to be impaired by leptomycin B (LMB), a compound which covalently 
modifies a critical cystein residue in CRM1 and thereby prevents CRM1-pp32 interaction 
via NES (31). Moreover, CRM1 has been shown to be instrumental in the nuclear export 
of HuR (26, 27). Our observation that ACTH treatment stimulates the formation of HuR-
pp32 complexes in the cytoplasm prompted us to examine the effect of LMB on ACTH-
induced increase in VEGF mRNA levels. BAC cells were stimulated with ACTH in the 
absence or in the presence of leptomycin B (LMB). As shown in Fig. 4A, the hormone-
induced increase of HuR in the cytoplasm was abolished at all time points of stimulation 
in the presence of LMB (5 ng/ml). 
RT-PCR analysis of VEGF mRNA levels revealed that co-treatment of BAC cells with 
ACTH and LMB prevented the increase in VEGF mRNA expression elicited by ACTH 
(Fig. 4B). Quantitation of two independent experiments showed that after 2 h of ACTH 
treatment, VEGF mRNA levels were induced up to 290 ± 60 % of control levels and that, 
in the presence of LMB, maximal induction reached only 147 ± 60 % of control levels. 
LMB also had a discrete effect by itself on the basal expression of VEGF mRNA.  
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To provide further evidence of the involvement of HuR in the regulation of VEGF mRNA 
expression by ACTH, we used RNA interference to more selectively target HuR. Using a 
specific siRNA targeting exon 2 in HuR gene, we showed by both RT-PCR and Western 
blotting that this siRNA was effective in decreasing HuR mRNA and protein levels in 
BAC cells after 48 h of treatment (Fig. 5A and 5B, time point 0). Quantitation of HuR 
mRNA level in three independent experiments revealed that HuR gene expression was 
knocked down by 70 to 85 % (data not shown). In these experiments, HuR protein levels 
were barely detectable upon prolonged exposure of the Western blot (data not shown). 
BAC cells pre-treated either in the presence of a negative control siRNA or in the 
presence of HuR siRNA were further stimulated with 10 nM ACTH and VEGF mRNA 
levels were analyzed by RT-PCR. In this particular experiment, cells pre-treated with 
negative control siRNA displayed a 2.5-fold increase in VEGF mRNA expression after 4 
h of exposure to ACTH (Fig. 5A and 5C). In contrast, HuR siRNA impaired ACTH-
elicited up-regulation of VEGF mRNA levels (Fig. 5A and 5C). Moreover, silencing HuR 
expression led to a substantial reduction in basal VEGF mRNA expression down to 39 ± 
19 % of controls (n=3, data not shown). 
 
Antagonistic effects of Tis11b and HuR on VEGF mRNA 
A previous study using co-transfections of Tis11b (pCMV-Tis11b) and firefly luciferase 
cDNA cloned upstream of VEGF mRNA 3’-UTR (Luc-V3’ construct) allowed us to 
demonstrate that VEGF mRNA 3’-UTR confers a Tis11b-mediated decrease in reporter 
gene activity, which was closely related to a decrease in luciferase transcript stability 
(30). Furthermore, similar experiments using co-transfections of HuR and Luc-V3’ 




anuscript    inserm
-00202064, version 1
in luciferase transcript stability (32). Because HuR and Tis11b appear to have 
antagonistic activity on VEGF mRNA and since the Tis11b binding site on VEGF mRNA 
3’-UTR is very close to a recently described HuR binding site (32), we investigated 
whether these two proteins could compete with each other to regulate VEGF mRNA 
expression. We first determined the effect of expressing each protein alone on luciferase 
activity. COS7 cells were transiently transfected with increasing doses of either pCMV-
Tis11b or pCMV-HuR plasmids and a fixed concentration of Luc-V3’. Fig. 6A shows that 
luciferase activity was decreased in a dose-dependent manner by Tis11b, a statistically 
significant decrease being observed with a plasmid amount as low as 0.5 ng (62.5 ± 7.9 
%, of controls, p<0.01, n=3). In contrast, HuR expression led to an increase in the 
reporter gene activity over a narrow window of the cotransfected HuR plasmid (Fig. 6B). 
A statistically significant increase of luciferase activity was observed with 0.1 ng of 
pCMV-HuR (156.8 ± 13.8 % of controls, p<0.001, n=3, Fig. 6A). Experiments were then 
performed to determine the competitive effects of HuR and Tis11b co-expression on 
VEGF mRNA 3’-UTR. As shown in Fig. 6C, the luciferase activity recorded following co-
transfection of 1 ng of pCMV-Tis11b and 0.1ng of pCMV-HuR was significantly lower 
than the luciferase activity obtained with 0.1 ng of pCMV-HuR alone (81.8 ± 2.3% as 
compared to 152.2 ± 6.3 % of controls, respectively, p<0.001, n=3). This inhibitory effect 
of Tis11b on HuR-induced luciferase activity was observed with a concentration of 
pCMV-Tis11b as low as 0.2 ng. Conversely, the luciferase activity measured following 
co-transfection of 1 ng of pCMV-Tis11b and 0.1ng of pCMV-HuR was significantly 
higher than the one measured with pCMV-Tis11b alone (81.8 ± 2.3% as compared to 
48.6 ± 2.1 % of controls, respectively, p<0.01, n=3). Western blot analysis of cell 
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express HuR protein but not Tis11b protein (Fig. 6C, lower panel). As expected, 
transfection of either 0.05 ng or 0.1 ng of pCMV-HuR plasmid led to an increased 
expression of HuR. By contrast, Tis11b expression was barely detectable with 0.2 ng of 
pCMV-Tis11b plasmid but clearly detected after transfection of 1 ng of plasmid.  
We next investigated the effect of HuR and Tis11b co-expression on Luc-V3’ mRNA 
levels (Fig. 6D). Northern blot analysis of COS7 total RNA revealed that transfection of 
0.1 ng of pCMV-HuR increased Luc-V3’ mRNA levels similarly to the reporter gene 
activity. Co-transfection of 0.2 and 1 ng of pCMV-Tis11b with 0.1 ng of pCMV-HuR 
abolished HuR-induced increase in Luc-V3’ mRNA. Finally, Luc-V3’ mRNA level was 
decreased in a dose-dependent manner by Tis11b. Altogether, these results suggest 
that Tis11b and HuR could antagonize each other to regulate VEGF mRNA expression 
through its 3’-UTR. 
 
Tis11b and HuR compete for binding to the 3’UTR of VEGF mRNA 
Because Tis11b and HuR appeared to antagonize each other in the regulation of VEGF 
mRNA expression, experiments were performed to determine whether these proteins 
could compete with each other for the binding to VEGF 3’-UTR. Tis11b-expressing 
bacterial extract was mixed with increasing amounts of purified GST-HuR fusion protein 
and purified GST-HuR was mixed with increasing amounts of Tis11b-expressing 
bacterial extract. These mixtures were exposed to UV light in cross-linking assays with 
VEGF 3’-UTR RNA probe. As shown in Fig. 7B, a covalent ribonucleoprotein complex 
with an apparent molecular weight of 38 kDa was detected when Tis11b-expressing 
bacterial extract was incubated with VEGF 3’-UTR (lane 2). This complex was not 
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covalent ribonucleoprotein complex with an apparent molecular weight of 64 kDa was 
detected when GST-HuR fusion protein was incubated with VEGF 3’-UTR (lane 6). 
When 1 µg of GST-HuR was added to 2 µg of Tis11b, both complexes of 38 and 64 kDa 
were detected, indicating that Tis11b and HuR could bind simultaneously to the VEGF 
3’-UTR RNA probe (lane 3). Increasing the amount of GST-HuR in the presence of 2 µg 
of Tis11b resulted in a slight decrease in the intensity of Tis11b-RNA complex and a 
corresponding increase in HuR-RNA complex (lanes 4 and 5). Increasing the amount of 
Tis11b in the presence of 1 µg of HuR resulted in a marked decrease in the intensity of 
HuR-RNA complex (lanes 7-9). Unexpectedly, no increase in Tis11b-RNA complex was 
observed, suggesting that optimal Tis11b binding to VEGF 3’-UTR requires additional 
factors which remain to be identified. Indeed, we could observe an increase of Tis11b- 
binding to VEGF 3’-UTR over a narrow window of Tis11b doses ranging from 1 to 3 µg, 
followed by a decrease of Tis11b-binding to VEGF 3’-UTR at higher doses (data not 
shown). Quantitation of 2-4 independent experiments shows that increasing doses of 
Tis11b markedly decreased HuR binding to VEGF 3’-UTR (to 23.2 ± 9.5 % of HuR 








Vascular endothelial growth factor VEGF has been shown in mammals to be a key 
mediator of angiogenesis in such diverse physiological and pathological processes as 
embryogenesis, female oestrus cycle, diabetic retinopathy and tumor development (1).  
The expression of the VEGF gene is controlled at many levels including transcription 
(10), mRNA stability through the binding of regulatory proteins to the 3’ untranslated 
region (33) and mRNA translation via IRES sequences located in the 5’ untranslated 
region (15). Post-transcriptional regulation of VEGF mRNA is a key control point in 
VEGF expression under hypoxic conditions. Indeed, hypoxia-mediated increase of 
VEGF mRNA levels is in a large part due to an increase in VEGF mRNA half-life 
following its stabilization by the RNA-binding protein HuR (11).  
Transcriptional regulation of VEGF expression by hormones in endocrine tissues, 
including endometrium, ovaries and adrenal cortex, has been extensively studied (34-
39). In contrast, the possible involvement of post-transcriptional regulation in 
hormonally-regulated expression of VEGF has received much less attention to date. We 
have previously shown that the trophic hormone ACTH triggers a rapid and transient 
increase in VEGF mRNA levels in adrenocortical cells via transcription-independent 
mechanisms (28). We could further demonstrate that the decay phase of ACTH-induced 
VEGF mRNA levels involves the RNA-destabilizing protein Tis11b (30). In the current 
study, we aimed at investigating the molecular mechanisms of ACTH-elicited increase in 
VEGF mRNA levels. Four major conclusions can be drawn from the present work: (1) 
ACTH induces a rapid delocalization of the RNA-stabilizing protein HuR from the 
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mRNA and protein levels. (2) Blocking nuclear export of NES-bearing proteins by 
leptomycin B impairs ACTH-induced expression of VEGF mRNA. (3) Silencing the 
expression of HuR by siRNA markedly inhibits ACTH-mediated induction of VEGF 
mRNA levels. (4) Tis11b and HuR exert an antagonistic action on VEGF mRNA in vitro. 
First, our finding that the levels of cytoplasmic and nuclear HuR are potently influenced 
by the trophic hormone ACTH provides a new insight into the regulation of HuR in 
adrenocortical cells, suggesting a connection between the ability of HuR to stabilize 
ACTH-induced labile mRNAs and the subcellular targeting of these mRNAs. Various 
other stimuli can shift the nucleo-cytoplasmic distribution of HuR. Cytoplasmic 
localization of HuR is associated with conditions of cellular stress including heat shock 
(40), UV irradiation (41), and amino acid starvation (42), as well as stimulation with LPS 
in the case of macrophages (43). HuR can bind to AU-rich regions in c-fos mRNA, a CU-
rich region in c-jun mRNA and a U-rich domain in c-myc and VEGF mRNAs (11, 20, 44, 
45), all of these genes being early-response genes to ACTH in the adrenal cortex (28, 
46). Our observation that ACTH induces an increase in cytoplasmic levels of HuR 
suggests that HuR may play a role in stabilizing these labile mRNAs. Our results 
showing that (i) HuR co-immunoprecipitates with the nucleocytoplasmic shuttling protein 
pp32 in the cytoplasm of ACTH-stimulated cells and (ii) ACTH increases transiently the 
association of HuR with pp32 in the cytoplasm argue that the hormone triggers nuclear 
export of HuR to the cytoplasm. Interestingly, there is accumulating evidence that the 
nuclear-cytoplasmic localization of HuR is modulated by signal transduction pathways 
(47-51). ACTH is known to increase intracellular cAMP levels in cultured adrenocortical 
cells. We have previously shown that raising endogenous cAMP levels by forskolin was 
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stimulation of BAC cells with ACTH in the presence of H89 (10 µM), a potent and 
specific inhibitor of the protein kinase A, completely abolished the hormone-induced 
increase of HuR in the cytoplasm (data not shown). Moreover, stimulation of BAC cells 
with forskoline (10 µM) led to a substantial increase of HuR levels in the cytoplasm (up 
to 165 % of HuR protein content of non-stimulated cells after 1-2 h of stimulation, data 
not shown). These observations suggest that cAMP and protein kinase A are involved in 
the hormone-induced delocalization of HuR to the cytoplasm. The potential targets of 
protein kinase A remain however to be determined in future studies. Since pp32 is a 
phosphoprotein (26), it is tempting to speculate that pp32 shuttling or its interaction with 
HuR could be regulated by phosphorylation. This hypothesis is worth testing since we 
failed to identify phosphorylated forms of HuR in response to ACTH (data not shown). 
Second, we observed that leptomycin B (LMB), a specific inhibitor of the nuclear export 
receptor CRM1 significantly impaired ACTH-induced increase in VEGF mRNA. Although 
it is possible that LMB inhibits other components of the nucleocytoplasmic trafficking 
machinery, we hypothesize that ACTH-induced association of pp32 and HuR most likely 
confers CRM1-dependent export on HuR. Therefore, disruption of the nuclear export of 
HuR protein partners by LMB might lead to retention of HuR in the nucleus, and thereby 
might impair ACTH-induced increase in VEGF mRNA levels. Indeed, we observed that 
LMB prevented the ACTH-mediated increase of HuR in the cytoplasm of BAC cells as 
well as the hormone-induced increase in VEGF mRNA levels, thus indicating that HuR 
export to the cytoplasm is instrumental in ACTH-induced VEGF mRNA. 
Because BAC cells already have a high level of HuR, defining the functions of HuR in 
the cellular response to ACTH using the overexpression approach could lead to effects 
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the role of HuR in ACTH-induced VEGF mRNA, we disrupted the expression of 
endogenous HuR in BAC cells using RNA interference (RNAi). Interestingly, RNAi-
mediated depletion of HuR leads to a complete inhibition of hormone-induced 
expression of VEGF, indicating that HuR is a limiting factor in the induction phase of 
VEGF mRNAs by ACTH. HuR expression was significantly reduced (by 80 to 85 %) 48 h 
before ACTH treatment. In our RNAi experiments in which HuR expression was reduced 
by only 70%, inhibition of ACTH-elicited VEGF mRNA levels was not complete (data not 
shown), suggesting that low levels of HuR were sufficient to stabilize VEGF mRNA. 
These results, together with those we reported on the involvement of the mRNA-
destabilizing protein Tis11b in the decay phase of ACTH-elicited VEGF mRNA levels, 
indicate that ACTH controls VEGF expression in adrenocortical cells mainly by post-
transcriptional mechanisms. The pivotal role of HuR in the stabilisation of VEGF mRNA 
by hypoxia has been extensively studied (52). To our knowledge, this work is the first to 
report a hormonal up-regulation of VEGF mRNA expression which is mediated by the 
RNA-stabilizing protein HuR.  
Fourth, concomitant overexpression of Tis11b and HuR revealed that Tis11b completely 
abrogated HuR-induced luciferase activity on a heterologous transcript consisting of 
luciferase cDNA cloned upstream of VEGF mRNA 3’-UTR (Luc-V3’). Our results 
showing that HuR increases luciferase activity derived from Luc-V3’ in vitro are similar to 
those reported by Goldberg-Cohen et al (32). Using a similar reporter construct, these 
authors have shown further that the increase in reporter activity was related to HuR 
binding to a 40-bp RNA element (nucleotides 1285-1325) within VEGF mRNA 3’-UTR, 
which confers increased stability to the heterologous transcript. Tis11b and HuR bind to 
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(30) and 1285-1325 (32) for Tis11b and HuR, respectively). Our UV cross-linking 
experiments indicate that Tis11b and HuR can simultaneously as well as individually 
bind to VEGF 3’-UTR RNA probe. However, Tis11b potently prevents HuR binding to 
VEGF 3’-UTR, a finding which is consistent with the inhibitory effect of Tis11b on HuR-
mediated increase in reporter gene activity and mRNA level (co-transfection 
experiments, Fig. 6C and 6D). For as yet unidentified reasons, the decrease in HuR-
binding to VEGF 3’-UTR in the presence of increasing doses of Tis11b was not 
paralleled by an increase in Tis11b binding. Similar results showing that HuR and 
tristetraprolin (Tis11, TTP), the most studied member of the Tis11 protein family, can 
bind simultaneously and competitively to GM-CSF 3’-UTR have been reported by 
Raghavan et al (53). More recently, Ashish et al provided evidence that HuR and the 
mRNA-destabilizing factor AUF1 can bind target transcripts on both distinct, non-
overlapping sites, and on common sites in a competitive fashion (54). They propose that 
the fate of the mRNA target depends on HuR and AUF1 abundance, the target RNA 
sequence and the subcellular compartment investigated. Experiments aiming at 
dissecting the molecular mechanisms governing the binding of Tis11b and HuR to 
specific or common sites on VEGF 3’-UTR are under way.  
At the functional level, following stimulation of adrenocortical cells by ACTH, HuR which 
predominates in the nucleus may shuttle to the cytoplasm where it may stabilize VEGF 
mRNA allowing it to be translated. Subsequently, Tis11b expression is induced and the 
cytoplasmic level of Tis11b increases. The relative levels and binding affinities of HuR 
and Tis11b for their specific sequences in VEGF mRNA 3’-UTR may determine the fate 
of VEGF transcripts, with HuR predominance promoting VEGF mRNA stabilisation and 
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and 6 h of stimulation by ACTH, according to our data), Tis11b may predominate and 
facilitate VEGF mRNA degradation. This model provides a mechanism by which VEGF 
gene could be transiently expressed in BAC cells. 
In conclusion, this work reports for the first time that ACTH triggers a rapid nuclear 
export of HuR into the cytoplasm of adrenocortical cells followed by an induction of 
Tis11b protein synthesis and cytoplasmic accumulation, two processes that appear to 
be responsible for the transient stimulation of VEGF mRNA and protein accumulation. In 
an in vivo model of adrenal cortex tissue regression triggered by the suppression of 
pituitary ACTH secretion, we recently observed that adrenocortical VEGF expression is 
dramatically reduced during this process, resulting in massive disorganization and 
regression of the capillary network (55). It will therefore be of great interest to establish 
the respective contributions of HuR and Tis11b to the in vivo regulation of adrenal 
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MATERIALS AND METHODS 
 
Reagents 
Synthetic ACTH1-24 was purchased from Neosystem (Strasbourg, France). Culture 
media and sera were from Invitrogen (Cergy Pontoise, France). All chemicals were 
obtained from Sigma (St Louis, MO) and were of the highest purity grade available. 
 
Bovine adrenocortical cell (BAC) culture and treatments 
Bovine adrenal glands were obtained from a local slaughterhouse. Zona fasciculata-
reticularis cells were prepared by enzymatic dispersion with trypsin and primary cultures 
were established as described in detail elsewhere (56). BAC cells were kept at 37 C in 
Ham’s F12 medium supplemented with 10% horse serum, 2.5% fetal calf serum, 100 
U/ml penicillin, 100 μg/ml streptomycin, 20 μg/ml gentamycin, under 5% CO2 - 95% air 
atmosphere.  On day 4, cells cultured in 10-cm petri dishes (3 x 106 cells/dish) were 
stimulated with 10 nM ACTH for the indicated periods of time before subcellular 
fractionation or processing for total RNA isolation as described hereafter. In experiments 
designed to silence HuR expression (RNAi), BAC cells were transfected on day 2 of 
culture. 
 
Preparation of subcellular fractions  
 
Total cell extracts, as well as nuclear and cytoplasmic fractions were prepared using the 
PARIS protein and RNA isolation kit (Ambion, Austin, TX) according to the 
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of aprotinin, 1 μg/ml of pepstatin and 25 μg/ml of AEBSF) was added to the provided 
buffers. Briefly, 10-cm petri dishes (3 x 106 BAC cells/dish) were lysed on ice in 400 μl of 
Cell Disruption buffer and collected with a rubber spatula. A portion of the total cell 
lysate was used for RNA isolation (300 μl) and the remainder was kept for protein 
analysis (100 μl).  
For nuclear and cytoplasmic lysate preparation, BAC cells (3 x 106 cells/ 10-cm petri 
dish) were trypsinized, washed in PBS then suspended in 400 μl of Cell Fractionation 
Buffer. Following a 15 min-incubation on ice, nuclear and cytoplasmic fractions were 
separated by centrifugation (5 min at 500 x g). The nuclear pellet was lysed in 400 μl of 
Cell Disruption buffer and kept 10 min on ice to ensure complete disruption before 
processing the sample for protein analysis. 
Protein concentration was determined using a Micro BCA protein Assay Kit (Pierce, 
Rockford, IL). 
 
RNA isolation and Reverse Transcription-Polymerase Chain Reaction 
BAC cell total RNA was extracted using the RNAgents kit (Promega Corp., 
Charbonnières, France) according to the manufacturer’s instructions. This system 
consistently yields 50-80 µg total RNA/3 x 106 cells. For RT-PCR analysis of Tis11b, 
VEGF, HuR or HPRT gene expression, 1 µg of total RNA were reverse transcribed with 
Superscript II reverse transcriptase (Invitrogen, Cergy Pontoise, France) and PCR 
amplified using Taq polymerase (QBiogen, Illkirch, France). Amplification of VEGF 
mRNA isoforms was performed using the primers and amplification conditions described 
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bp for the two major VEGF transcripts, VEGF165 and VEGF121, respectively. The primers 
for PCR of Tis11b were as follows: 5’-CGAAGAAAACGGTGCCTGTAAG-3’ and 5’-
AGTAGGTGAGCCCAAGAGGTCATC-3’. This primer pair sequence amplifies a 354-bp 
fragment. The amplification conditions were as follows: 94° C for 5 min followed by 25 
amplification cycles, each consisting of 94°C for 1 min, 55°C for 1 min, 72°C for 1 min, 
and 72°C for 5 min for final extension. The primers for HPRT amplification were as 
follows:  5’-GCCATCACATTGTAGCCCTCT-3’ and 5’-TGCGACCTTGACCATCTTTGG-
3’. This primer pair sequence amplifies a 305-bp fragment. The amplification conditions 
were as follows: 94° C for 5 min followed by 25 amplification cycles, each consisting of 
94°C for 1 min, 55°C for 1 min, 72°C for 1 min, and 72°C for 5 min for final extension.  
The primers for HuR amplification were as follows: 5’-
ATGACCCAGGATGAGTTACGAAGC-3’ and 5’-GTTCACAAAGCCATAGCCCAAG-3’. 
This primer pair sequence amplifies a 111-bp fragment. The amplification conditions 
were as follows: 94° C for 5 min followed by 25 amplification cycles, each consisting of 
94°C for 1 min, 52°C for 1 min, 72°C for 1 min, and 72°C for 5 min for final extension. 
PCR products were analyzed on 2% agarose ethidium bromide-containing gels and 
quantitated using ImageQuant software (FluorImager SI, Vistra Fluorescence). 
Preliminary experiments were done to select the starting amounts of RNA so that there 
was a linear relationship between the amount of input RNA and the optical density of the 
HPRT band on ethidium bromide-stained gel.  
 
SDS-Polyacrylamide Gel Electrophoresis 
SDS-polyacrylamide gel electrophoresis was performed according to Laemmli (57). 
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buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 5% β-mercaptoethanol, 10% glycerol, 0.01% 
bromophenol blue), boiled for 5 min and loaded onto a 12% SDS-PAGE minigel (Mini 
Protean II System, BioRad). Electrophoresis was performed at 150 V for 1 h. 
 
Western blot analysis 
SDS-PAGE-resolved proteins were electrophoretically transferred onto a PVDF 
membrane according to Towbin et al. (58). Following transfer, the membrane was 
incubated in a blocking buffer (PBS buffer containing 0.1% Tween 20 and 5% non-fat 
dry milk) for 1 h at room temperature. The blots were probed sequentially with 
antibodies to a peptide fragment (amino acids 49-63) of Tis11b protein (1:500, CovalAb, 
Lyon, France), anti-human HuR (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), 
monoclonal anti-α-tubulin (1:200000, a generous gift from Dr D. Job, CS-U366 INSERM, 
CEA-Grenoble, France), and anti-lamin A/C (1:15000, a generous gift from Dr. 
Deloulme, TS-EMI 01-04 INSERM, CEA-Grenoble, France) for 2 h in PBS containing 
0.1% Tween. The membrane was thoroughly washed with the same buffer (3 x 10 min), 
then incubated for 1 hour with either horseradish peroxidase (HRP)-labelled goat anti-
rabbit IgG (immunodetection of Tis11b and HuR) or HRP-labelled goat anti-mouse IgG 
(immunodetection of tubulin), or HRP-labelled goat anti-guinea pig IgG 
(immunodetection of lamin A/C). The PVDF sheet was washed as above and the 
antigen-antibody complex revealed by Enhanced Chemiluminescence, using the 
Western blotting detection kit from Amersham Biosciences (Buckinghamshire, England) 
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Immunoprecipitation assay 
BAC cells cultured in 10-cm petri dishes (3 x 106 cells / dish) were stimulated with 10 nM 
ACTH for the indicated periods of time. Subcellular fractions (cytoplasm and nuclei) 
were prepared as indicated previously. Lysates was cleared by centrifugation for 5 min 
at 12,000 x g at 4 C. The anti-human pp32 (I1PP2A) polyclonal antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) was added at a concentration of 2 µg/ml to whole 
supernatants (about 250 µg protein for cytoplasm and 70 µg protein for nuclei), which 
were then gently rocked for 2 h at 4 C, before being incubated for 30 min with Protein 
A/G Sepharose beads. Immunoprecipitates were pelleted, washed four times with RIPA 
buffer, analyzed by SDS-PAGE and transferred to a PVDF membrane. Blots were 
probed with anti-HuR or anti-pp32 antibodies which were used at 1:1,000. 
 
RNA interference 
Expression of HuR (ELAVL1, GenBank accession no NM_001419) was inhibited by 
transfection of a pre-designed siRNA duplex targeted to exon 2 of human HuR gene 
(Ambion, Austin, TX). siRNA sense and antisense sequences were 5’-
GGAUGAGUUACGAAGCCUGtt-3’  and 5’-CAGGCUUCGUAACUCAUCCtt-3’, 
respectively. One day after plating, adrenocortical cells were transfected with 10 nM of 
either HuR siRNA duplex or negative control siRNA (Ambion), using siPORT lipid 
reagent (Ambion). Typically, cells were analyzed for the loss of HuR mRNA and protein 
expression 48 hours after transfection using RT-PCR and immunoblotting. At this time 
point, culture medium was changed and cells were treated for the indicated periods of 
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Transient Transfections and Dual Luciferase Activity Assay 
COS7 cells were grown in DMEM supplemented with 10% fetal calf serum, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 25 μg/ml gentamycin, and transfected in 12 well-
plates using lipofectamine (Invitrogen, Cergy-Pontoise, France) according to the 
manufacturer’s recommendations. Plasmid pLuc-V3’ contains the firefly luciferase cDNA 
cloned upstream of the rat VEGF 3’ UTR and downstream of the thymidine kinase (TK) 
promoter (30). Plasmid pCMV-murine HuR was provided by Dr Jonathan LaMarre 
(University of Guelph, Ontario, Canada). pCMV-Tis11b plasmid was described 
previously (30). pRL-TK encoding renilla luciferase was obtained from Promega Corp. 
(Charbonnières, France). 
Various amounts of either pCMV-Tis11b, pCMV-HuR or both (0.05-1 ng) were co-
transfected with 500 ng pLuc-V3’, 25 ng of pRL-TK, and pUC19 up to a total of 700 ng 
plasmid DNA into 1.5 x 105 cells. Renilla and firefly luciferase activities were measured 
sequentially 48 h after transfection with the Dual-Luciferase reporter assay system 
(Promega Corp.) on a LUMAT LB 9507 luminometer (EGG-Berthold, Bad, Wildbad, 
Germany). Results are expressed as relative light units of firefly luciferase activity over 
relative light units of renilla luciferase activity to compensate for variations in transfection 
efficiency. Each transfection condition was performed in triplicate. 
 
Northern hybridization 
COS7 cells total RNA was extracted using the RNAgents kit (Promega,) according to the 
instructions of the manufacturer. 15–20 µg RNA were size-fractionated on a 1% 
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(Amersham) and fixed by UV cross-linking. Northern blots were pre-hybridized in Rapid 
Hybridization Buffer (Amersham) at 65 C for 30 min. [α32P]dCTP labeled luciferase 
cDNA probe (2 x 106 cpm / ng DNA, Rediprime random primer labeling kit, Amersham) 
was then added and the incubation was continued for 2 h at 65 C. Blots were washed 
for 5 min and 15 min successively at room temperature in 2 x saline sodium citrate 
(SSC), 0.1% SDS, and then for 15 min in 1 x SSC, 0.1% SDS. The final wash was 
performed at 65 C for 15 min in 0.5 x SSC, 0.1% SDS. RNA-cDNA hybrids were 
visualized on phosphor screen (Molecular Dynamics) after a 12- to 24-h exposure 
period. Blots were stripped and reprobed with 18s cDNA probe to assess RNA loading. 
 
Recombinant protein expression and purification 
Tis11b recombinant protein was produced as reported in (30). GST-HuR fusion protein 
was produced using E. Coli BL21 strain transformed with pGEX-5X2-HuR plasmid 
(provided by Dr JA Steitz, Yale University school of Medicine, New Haven, USA). 
Bacteria were grown at 37°C to an A600 nm of 0.6 in 2YT medium (16 g/l tryptone, 10 g/l 
yeast extract, 5 g/l NaCl) containing 100 µg/ml of ampicillin. The GST-HuR fusion 
protein was induced with 0.1 mM IPTG for 2 hours, and purified using MicroSpin GST 
Purification Module (Amersham Biosciences) according to the manufacturer’s 
instructions. Briefly, cells were harvested by centrifugation (2,500 x g at 4 C for 5 min). 
The pellet was resuspended with ice-cold PBS containing 0.1 mg/ml lysozyme and lysed 
by repeated freeze/thawing (10 times). Clarified lysate was mixed for 10 min with 
Glutathione Sepharose 4B Microspin column. After two washes with PBS, GST-HuR 
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was examined by Coomassie blue staining following SDS-PAGE analysis. 
 
RNA-protein UV cross-linking assay 
[32P]-rUTP labeled and unlabeled riboprobes were synthesized in vitro using pSp64 
plasmid containing the entire VEGF 3’-UTR and the Riboprobe SP6 in vitro Transcription 
System (Promega). Integrity of RNA transcripts was visualized on 1% agarose ethidium 
bromide-containing gel. 1 x 106 cpm of RNA transcripts were incubated for 20 min at 
room temperature with 1 to 6 µg of either Tis11b-containing bacterial extract or GST-
HuR fusion protein, in 10 mM HEPES pH 7.6, 3 mM MgCl2, 40 mM KCl, 5% glycerol, 
0,5% NP40 and 2 mM DTT. Yeast tRNA (50 ng/µl) and heparin (2 µg/µl) were then 
added for 10 min. Mixtures were exposed to UV light for 30 min on ice. 100 U of RNase 
T1 (Invitrogen) were then added for 20 min and RNA-protein complexes were analyzed 
by 12% SDS-PAGE and autoradiography. 
 
Statistical analysis 
Results are expressed as means ± S.E. The mean values were compared by ANOVA 
using Fisher's test. A value of p<0.05 was considered as statistically significant. 
Quantitation of immunoblots and autoradiograms was performed using a Molecular 
Imager FX and Quantity One software (Biorad).  
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Figure 1: Effect of ACTH on VEGF, Tis11b and HuR mRNAs expression.  
A, Representative ethidium bromide staining of VEGF, Tis11b and HuR mRNAs 
amplified by RT-PCR. Primary cultures of BAC cells were treated with 10 nM ACTH 
for the indicated periods of time. VEGF, Tis11b and HuR mRNA levels were then 
analyzed by RT-PCR as described in Materials and Methods. B, Quantitation of 
VEGF, Tis11b and HuR mRNAs levels of independent experiments (n=3 to 5). mRNA 
level values were normalized to HPRT mRNA levels and are expressed as fold 
induction over control values at time 0 (unstimulated cells).  
 
Figure 2: Effect of ACTH on Tis11b and HuR protein levels in total cell extracts and 
subcellular fractions.  
A, BAC cells were treated with 10 nM ACTH for the indicated periods of time. Tis11b 
and HuR protein levels of whole cell extracts (10 μg) were analysed by Western blot 
as outlined in Materials and Methods. The Western blot was subsequently probed 
with an anti-α-tubulin monoclonal antibody to assess equal loading of samples. B, 
Quantitation of HuR and Tis11b protein levels of total cell extracts in three 
independent experiments. Protein level values were normalized to α-tubulin protein 
levels. C, BAC cells were treated with 10 nM ACTH as indicated in (A). Nuclear (5 
μg) and cytoplasmic (20 μg) fractions were prepared as described in Materials and 
Methods and subjected to Western blot analysis to monitor Tis11b and HuR 
expression. The same membranes were sequentially probed with antibodies 
recognizing cytoplasm- and nucleus-specific proteins (α-tubulin and lamin A/C, 
respectively) to assess the quality of the fractionation process and to check for equal 
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tubulin and lamin protein levels respectively and are expressed as a fraction of total 
cytoplasmic or total nuclear protein content (n=2). 
 
Figure 3: Co-immunoprecipitation of HuR from BAC cytoplasmic and nuclear extracts 
using anti-pp32 antibodies. 
A, BAC cells were treated with 10 nM ACTH for the indicated periods of time. 
Cytoplasmic (250 µg protein) and nuclear fractions (70 µg protein) were 
immunoprecipitated with anti-human pp32 antibodies as mentioned in Materials and 
Methods. Precipitates were electrophoresed on a 12% denaturing gel, transferred to 
PVDF membrane, and probed with HuR or pp32 polyclonal antibodies. B, 
Quantitation of HuR levels in cytoplasmic and nuclear extracts. HuR protein levels 
were normalized to the IgG light chain bands. 
 
Figure 4: Effect of Leptomycin B (LMB) on ACTH-induced increase in VEGF mRNA 
levels.  
A, BAC cells were treated with 10 nM ACTH for the indicated periods of time, in the 
presence or in the absence of Leptomycin B (5 ng/ml). When used, LMB was added 
15 min before ACTH treatment. Cytoplasmic (30 μg) and nuclear fractions (5 μg) 
were subjected to Western blot analysis of HuR. B, Representative ethidium bromide 
staining of VEGF mRNA levels amplified by RT-PCR in BAC cells stimulated with 
ACTH in the presence or in the absence of LMB (5 ng/ml). C, Quantitation of VEGF 
mRNA levels in BAC cells stimulated with ACTH in the presence or in the absence of 
LMB, expressed as fold induction of mRNA levels at time 0 (unstimulated cells). Each 
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Figure 5: Effect of HuR repression by RNAi on ACTH-induced increase in VEGF 
mRNA levels.  
A, BAC cells were transfected either with HuR specific siRNA or a negative control 
siRNA as described in Materials and Methods. Forty-eight hours later, culture 
medium was changed and cells were treated for the indicated periods of time with or 
without 10 nM ACTH. At each time point of stimulation, total RNA was isolated and 
RT-PCR analysis was performed to determine HuR, VEGF or HPRT mRNA 
expression levels. B, Western blot analysis of HuR protein levels in whole-cell 
extracts (10 μg), showing that HuR siRNA was effective in knocking down HuR 
protein levels. In this particular experiment, blots for HuR were exposed for 2 min. 
Despite prolonged exposure of the membrane (15 min), HuR was barely detectable 
in protein extracts derived from HuR siRNA-treated cells. C, Quantitation of the RT-
PCR experiment represented in (A), in which HuR repression was evaluated to 85 %. 
Results obtained from three independent experiments revealed that ACTH-induced 
increase in VEGF mRNA levels was altered to a lesser extent when HuR repression 
was about 70% (data not shown).  
 
Figure 6: Antagonistic effects of Tis11b and HuR in the regulation of VEGF mRNA 
stability.  
COS7 cells were transfected as outlined in Materials and Methods. The pLuc-V3’ 
construct contains the full-length 3’-UTR of the rat VEGF mRNA (2201 bp) (30). A, 
Dose-dependent effect of Tis11b on pLuc-V3’ reporter gene activity. Results are 
expressed as relative light units of firefly luciferase activity over relative light units of 
renilla luciferase activity. B, Dose-dependent effect of HuR on pLuc-V3’ reporter gene 
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activity. The dose giving the maximal effect of HuR on luciferase activity (0.1 ng) was 
used with 0.2 or 1 ng of Tis11b to perform competition studies. Transfections were 
performed in triplicate and values are means ± S.E from three independent 
experiments. +, +++, significantly different from control (0 ng of pCMV-Tis11b or 
pCMV-HuR) with p<0.05 and p<0.001, respectively. There was a statistically 
significant decrease in luciferase activity for (HuR 0.1 ng + Tis11b 1 ng) compared to 
HuR 0.1 ng (***, p<0.001), as well as a statistically significant increase in luciferase 
activity for (HuR 0.1 ng + Tis11b 1 ng) compared to Tis11b 1 ng (**, p<0.01). There 
was a statistically significant decrease in luciferase activity for (HuR 0.1 ng + Tis11b 
0.2 ng) compared to HuR 0.1 ng (**, p<0.01), as well as a statistically significant 
increase in luciferase activity for (HuR 0.1 ng + Tis11b 0.2 ng) compared to Tis11b 
0.2 ng (**, p<0.05). In the lower panel, COS7 cell extracts (10 µg) were 
immunoblotted using anti-HuR or anti-Tis11b antibodies to check for HuR and Tis11b 
protein expression in transfected cells. HuR and Tis11b are indicated with arrows. In 
this cell line, Tis11b is indetectable at basal levels. D, Effect of Tis11b and HuR co-
expression on pLuc-V3’ reporter gene mRNA levels. COS7 cell total RNA (20 µg) 
were analyzed by Northern blot as indicated in Materials and Methods.   
 
Figure 7: Binding of HuR and Tis11b to VEGF 3’-UTR RNA. 
A, Restriction map of the 2201 bp-long 3’-UTR of VEGF mRNA. Tis11b binding 
element (TBE) is located between nucleotides 1161 and 1235 (30). The 40-bp 
functional HuR binding site is located between nucleotides 1285 and 1325 (32). 
Flags with white circles represent the nonameric ARE motifs UUAUUUA(A/U)(A/U) 
and those with black circles represent the pentameric motif AUUUA. B, VEGF full 
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Tis11b (2 µg) and increasing doses of purified GST-HuR (0, 1, 2, or 5 µg) or purified 
GST-HuR (1µg) and increasing doses of Tis11b (0, 2, 4, or 6 µg). The reaction 
mixtures were treated with UV radiation and were analyzed by electrophoresis as 
outlined in Materials and Methods. The positions of migration of the HuR and Tis11b 
RNA-protein complexes are indicated with arrows, (ns) represents a non-specific 
band observed with the control bacterial extract. C, Quantitation of Tis11b binding to 
VEGF 3’-UTR in the presence of increasing doses of HuR (squares) and of HuR 
binding to VEGF 3’-UTR in the presence of increasing doses of Tis11b (circles) in 2 
to 4 independent experiments. 100 % represents either the binding of Tis11b in the 
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